Clinical trials: Innate Immunity
Respiratory Infection
Human Lung Responses to Respiratory Pathogens
For most individuals, the lung has a remarkable ability to deal with exposure to a variety of inhaled bacteria. Some individuals, however, do have recurrent bacterial infections, usually in the form of acute or chronic bronchitis…
- Trial name
- NCT01967628
- Testing
- Vitamin D3 (cholecalciferol)
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Influenza
The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
This study will examine the immune responses to the seasonal influenza vaccine in single cells of the nasal passages when compared with cells in circulating blood.
- Trial name
- NCT03023553
- Testing
- Fluzone®, FluMist®
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Stanford University
Non-target Heterologous Effects of Vaccines, Vaccine Interactions
The Interaction Between Measles and DTP Vaccination
The purpose of this study is to investigate for the broad immunological effects of administering measles vaccine (MV) and diphtheria-tetanus-whole cell pertussis vaccine (DTP) to 9 month old Gambian infants, either alone or…
- Trial name
- NCT02710045
- Testing
- Measles Vaccine at 9 months of age, DTP Vaccine at 9 months of age, Measles Vaccine at 18 months of age
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Medical Research Council Unit, The Gambia
Transfemoral Amputation
Microbiome and Metagenome in Percutaneous Osseointegrated Prostheses (MMPOP)
The purpose of this study is to investigate the clinical implementation of a new percutaneous prosthetic attachment system by determining the resident microbial ecology of the implant exit site and to simultaneously study the…
- Trial name
- MMPOP (NCT02564432)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- VA Office of Research and Development
Neoplasms, Pancreatic
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis.
- Trial name
- NCT03681951
- Testing
- GSK3145095, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline